As breast cancer remains one of the most common cancers among women worldwide, innovation in oncologic treatments is more essential than ever. One such advancement is Ribociclib Succinate, a next-generation CDK 4/6 inhibitor that is transforming hormone receptor-positive breast cancer care.
How Does Ribociclib Succinate Work?
Ribociclib Succinate is designed for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, often in combination with endocrine therapy. It selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6)—proteins that play a crucial role in cell cycle progression. By blocking CDK4/6 activity, Ribociclib effectively halts cancer cell proliferation, helping slow tumor growth and improve patient outcomes.
This mechanism makes it a key component in combination targeted therapy, typically used alongside hormonal treatments such as aromatase inhibitors or fulvestrant.
Why Choose Suanfarma’s Ribociclib Succinate?
At Suanfarma, we support cutting-edge cancer therapies with reliable and high-quality APIs. Here’s why our Ribociclib Succinate is the ideal choice for your oncology pipeline:
🔹 High Purity & Low Impurities – With purity >98% and total impurities around 0.1%, our product ensures safety and effectiveness for final drug formulations.
🔹 Polymorphic Form A Confirmed – Suanfarma’s Ribociclib Succinate is produced in its stable and validated polymorphic form A, enhancing formulation predictability and regulatory compliance.
🔹 Advanced Manufacturing Capabilities – Produced under GMP conditions with annual production capacity of up to 500 kg, our facilities operate under OEB 4 safety standards with robust engineering controls.
🔹 Ready for Industrial Scale – Industrial quantities of Ribociclib Succinate will be available by Q3 2025, allowing you to plan ahead and meet growing global demand.
🔹 Regulatory-Ready – Supported by strict compliance with ICH guidelines and approvals from leading global authorities, including the FDA, EMA, PMDA Japan, NMPA, and WHO.
🔹 Global Market Growth – With 1.5 million potential patients annually and a CAGR over 7.3% (2023–2033), the global demand for Ribociclib continues to rise.
🔹 Flexible Particle Size Distribution – Current PSD is D90<200µm, but it can be adapted to customer needs for specific formulations.
Our focus is on developing APIs that enable pharmaceutical companies to bring best-in-class treatments to market. With our Ribociclib Succinate, you’re not just getting a high-quality ingredient—you’re gaining a strategic partner committed to the future of breast cancer treatment.
